WHO Sounds Alert Over Acute Scarcity of Weight-Loss Medications

Fewer than one in 10 patients eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the World Health Organization as it issues its initial recommendations on the medications.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to this class of drugs.

Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.

"The latest guidance recognises that obesity is a lifelong illness that can be treated with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and supply-chain constraints are significant hurdles to universal availability to the jabs that can help people shift significant body mass, explains the body.

Skinny Jab Shortage

Even in the present best projected outlook, the production of these medications might only reach around 100 million people – fewer than 10% of the global need, per the health organization.

The guideline encourages countries and companies to expand access, by measures like patent sharing.

Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.

The Way Weight-Loss Drugs Operate

GLP-1 drugs replicate a body's own hormone to delay gastric emptying, reduce hunger and increase the sense of being full so individuals eat less.

Patients typically see weight reduction in the initial weeks of starting on the regular doses.

Studies points to patients may put most of the weight back on within a year of halting the medication, as their typical appetite resume.

To be above a healthy weight elevates your likelihood for developing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.

Obesity concerns people in all nations and was responsible for 3.7 million deaths worldwide in 2024, per the health agency.